Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342947 | 0.86 | CA12 (0.50) | CTSKCTSSSYKCA12CA1 | |
| SCHEMBL9218191 | 0.86 | CA12 (0.50) | CTSKCTSSSYKCA12CA1 | |
| SCHEMBL8951255 | 0.86 | CA12 (0.50) | CTSKCTSSSYKCA12CA1 | |
| SCHEMBL5699570 | 0.79 | GAA (0.49) | CTSKALDH1A1RECQL | |
| SCHEMBL15757259 | 0.75 | CTSK (0.43) | CTSKCTSSCA12CA1CA7 | |
| SCHEMBL6245825 | 0.74 | CTSS (0.51) | CTSKCTSSALDH1A1CA12CA1 | |
| SCHEMBL3425341 | 0.74 | CA12 (0.49) | CTSKCTSSALDH1A1RECQLSYK | |
| SCHEMBL8442388 | 0.74 | KMT2A (0.53) | ALDH1A1CA12CA1 | |
| SCHEMBL22059597 | 0.74 | CA12 (0.49) | CTSKCTSSALDH1A1RECQLSYK | |
| SCHEMBL8442319 | 0.74 | KMT2A (0.53) | ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104496843-B | Method for synthesizing ubenimex | 山东益康药业股份有限公司 | 2017-02-22 | — | — | CN | disclosed |